Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for BioNexus Gene Lab (BGLC) over the last 5 years, with Q3 2025 value amounting to $11264.0.

  • BioNexus Gene Lab's Current Deferred Revenue fell 5067.01% to $11264.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11264.0, marking a year-over-year decrease of 5067.01%. This contributed to the annual value of $95879.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, BioNexus Gene Lab's Current Deferred Revenue stood at $11264.0, which was down 5067.01% from $11348.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Current Deferred Revenue ranged from a high of $95879.0 in Q4 2024 and a low of $107.0 during Q1 2022
  • Moreover, its 5-year median value for Current Deferred Revenue was $11348.0 (2025), whereas its average is $23758.7.
  • Per our database at Business Quant, BioNexus Gene Lab's Current Deferred Revenue crashed by 7007.74% in 2022 and then soared by 1421962.62% in 2023.
  • Over the past 5 years, BioNexus Gene Lab's Current Deferred Revenue (Quarter) stood at $77276.0 in 2021, then plummeted by 70.08% to $23123.0 in 2022, then crashed by 64.46% to $8218.0 in 2023, then skyrocketed by 1066.7% to $95879.0 in 2024, then tumbled by 88.25% to $11264.0 in 2025.
  • Its Current Deferred Revenue stands at $11264.0 for Q3 2025, versus $11348.0 for Q2 2025 and $21964.0 for Q1 2025.